2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. c-Met/HGFR

c-Met/HGFR

c-Met/HGFR

Related Products

PDF 1.01 MB

c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymalorigin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-100946
    CEP-40783
    		Inhibitor 99.12%
    CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.
    CEP-40783
  • HY-50703
    MK-2461
    		Inhibitor 99.61%
    MK-2461 is an ATP-competitive, selective and orally active wild-type and mutant c-Met inhibitor (IC50s: 0.4-2.5 nM). MK-2461 also inhibits Ron (IC50 of 7 nM) and Flt1 (IC50 of 10 nM), MK-2461 shows selective for c-MET over other kinases (lC50s = 22-7800 nM). MK-2461 can be used for the study of cancer, such as gastric cancer.
    MK-2461
  • HY-12017
    PF-04217903
    		Inhibitor 99.85%
    PF-04217903 is a potent ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met. PF-04217903 shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties.
    PF-04217903
  • HY-132814
    Fosgonimeton
    		Agonist 98.24%
    Fosgonimeton (ATH-1017) is a hepatocyte growth factor receptor (c-Met/HGFR) agonist. Fosgonimeton has neuroprotective effects in both LPS (HY-D1056) -induced neuroinflammation and Aβ-induced AD models.
    Fosgonimeton
  • HY-125017
    Bozitinib
    		Inhibitor 98.88%
    Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily.
    Bozitinib
  • HY-107145A
    Ningetinib
    		Inhibitor 99.82%
    Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2/KDR/Flk-1 and Axl, respectively.
    Ningetinib
  • HY-P99196
    Ficlatuzumab
    		Inhibitor 99.21%
    Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion.
    Ficlatuzumab
  • HY-10991
    MGCD-265 analog
    		Inhibitor 98.47%
    MGCD-265 analog is a potent and oral active inhibitor of c-Met and VEGFR2/KDR/Flk-1 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity.
    MGCD-265 analog
  • HY-P99455
    Bafisontamab
    		Inhibitor
    Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity.
    Bafisontamab
  • HY-103714
    Ensartinib
    		Inhibitor 99.93%
    Ensartinib (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively.
    Ensartinib
  • HY-15240
    c-Kit-IN-1
    		Inhibitor 98.83%
    c-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with IC50s of <200 nM.
    c-Kit-IN-1
  • HY-P99217
    Rilotumumab
    		Inhibitor 99.10%
    Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.
    Rilotumumab
  • HY-10421
    Tyrosine kinase inhibitor
    		Inhibitor 99.88%
    Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor.
    Tyrosine kinase inhibitor
  • HY-P5904
    Caveolin-1 (82-101) amide (human, mouse, rat)
    		Inhibitor 98.48%
    Caveolin-1 (82-101) amide (human, mouse, rat) (Caveolin-1 scaffolding domain peptide) is a peptide that reverses aging-associated deleterious changes in multiple organs. Caveolin-1 (82-101) amide (human, mouse, rat) inhibits tyrosine kinases.
    Caveolin-1 (82-101) amide (human, mouse, rat)
  • HY-123856
    MY10
    		Activator 99.87%
    MY10 is a potent and orally active receptor protein tyrosine phosphatase (RPTPβ/ζ) inhibitor. MY10 reduces NF-κB p65 expression. MY10 activates tyrosine phosphorylation of c-Met. MY10 prevents the alcohol-induced downregulation of Ptprz1 and Alk expression. MY10 attenuates binge-like ethanol consumption and ethanol reward. MY10 can be used in the study of neurological and vascular diseases.
    MY10
  • HY-16590
    X-376
    		Inhibitor 98.10%
    X-376 is a potent and highly specific ALK tyrosine kinase inhibitor (TKI) (IC50=0.61 nM). X-376 is a less potent inhibitor of MET (IC50=0.69 nM). X-376 displays potent anti-tumor activity.
    X-376
  • HY-18309
    MET kinase-IN-4
    		Inhibitor 99.46%
    MET kinase-IN-4 is an orally active Met kinase inhibitor. MET kinase-IN-4 has potent Met kinase inhibitory activity with an IC50 value of 1.9 nM. MET kinase-IN-4 can be used for the research of cancer.
    MET kinase-IN-4
  • HY-160506
    PRO-6E
    		Degrader 99.85%
    PRO-6E is an oral active PROTAC based on Cereblon ligand, and induces the degradation of MET with maximum degradation of 81.9% at 1 μM in MKN-45 cells. PRO-6E inhibits tumor growth in vivo and in vitro. PRO-6E induces cell apoptosis and induces cell arrest (Sturcture Note:(Blue: Cereblon ligand (HY-103596), Black: linker；Pink: ALK/c-Met inhibitor Crizotinib (HY-50878)).
    PRO-6E
  • HY-10261B
    (E/Z)-Afatinib
    		Inhibitor 99.98%
    (E/Z)-Afatinib ((E/Z)-BIBW 2992) is the mixture of (E)-Afatinib and (Z)-Afatinib. Afatinib (HY-10261) is an irreversible inhibitor of EGFR, by irreversibly binding to their ATP binding site to block activation of EGFR, HER2, HER4, and EGFRvIII. Afatinib used in co-administration with Temozolomide (HY-17364), potently targeting to EGFRvIII-cMet signaling in glioblastoma cells.
    (E/Z)-Afatinib
  • HY-100509
    NPS-1034
    		Inhibitor ≥98.0%
    NPS-1034 is a dual inhibitor of AXL and MET with IC50s of 10.3 and 48 nM, respectively.
    NPS-1034
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity